Financing, Equity Capital Markets

Dyne Therapeutics, Inc.

01/21
|
$168.0 Million
Piper Sandler served as bookrunner for Dyne Therapeutics, Inc. on a follow-on offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma